α粒子放射性药物在骨转移瘤治疗中的应用进展

骨骼是晚期恶性肿瘤的常见转移部位之一，骨转移瘤不仅会导致顽固性骨痛、病理性骨折等骨相关事件（SRE）的发生，还会导致医疗费用的增加和死亡风险的上升。放射性药物内放射治疗具有疗效好、靶向性好和毒性低等优点。常用于治疗骨转移瘤的放射性药物主要是释放β粒子和α粒子的药物，其中释放β粒子的放射性药物的临床应用较成熟，但也具有一定的局限性。近年来，释放α粒子的放射性药物越来越多地用于骨转移瘤的治疗，其在缓解骨痛、降低SRE发生率、延长总生存期等方面具有更大的优势。笔者仅就α粒子放射性药物在骨转移瘤治疗中的应用进展进行综述。

Application and progress of α-particle radiopharmaceuticals in the treatment of bone metastases

Bone is one of the common metastatic sites of advanced malignant tumors. Bone metastases not only lead to bone-related events (SRE), such as intractable bone pain and pathological fractures, but also result in the increase of medical costs and the risk of death. Internal radiotherapy with radiopharmaceuticals has the advantages of good curative effect, good targeting, and low toxicity. The radiopharmaceuticals commonly used in the treatment of bone metastases are those that release β-particles and α-particles. The clinical application of radiopharmaceuticals releasing β-particles is mature but has some limitations. In recent years, radiopharmaceuticals releasing α-particles are increasingly used in the treatment of bone metastases, because they have greater advantages in relieving pain, reducing the incidence of SRE, and prolonging overall survival than radiopharmaceuticals releasing β-particles. In this work, the authors review the progress in the application of α-particle radiopharmaceuticals in the treatment of bone metastases.